On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023's message of continuing to increase visibility and generate change for the millions of people globally living with...
Over 90% of adults above the age of 50 carry the virus that causes shingles; yet only 3% of Singaporeans in this age group believe they are at high...
GSK holds Shingles Awareness Week to educate Singaporeans about shingles and the importance of protection against it SINGAPORE, Feb. 28, 2023 /PRNewswire/ -- A GSK-sponsored Ipsos-MORI survey revealed only 3% of Singaporeans aged 50-79 years believe they are at high risk of developing shingles in the next 12 months. The survey among 200 respondents further reported that while 40%...
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology
Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related...
CStone announces China’s NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
This supplementary new drug application was filed for the fourth indication for sugemalimab in China, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclonal antibody to treat gastric/gastroesophageal junction adenocarcinoma. In November 2022, the GEMSTONE-303 study met its...
Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the first participant with neovascular age-related macular degeneration (nAMD) has been successfully dosed in the phase 1 clinical...
Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today held a ceremony to celebrate the initiation of operations and successfully carrying out trial production runs at its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang...
WAT Med initiates collaborative research study with The Ohio State University to test the effectiveness of EmeTerm – neuromodulation technology to manage nausea and vomiting
VANCOUVER, BC, Feb. 28, 2023 /PRNewswire/ -- The study recruits patients who suffer from chronic nausea and vomiting. EmeTerm Explore's antiemetic effectiveness will be tested and measured using subjective responses and objective physiological data from the patients. WAT Med initiates collaborative research study with The Ohio State University to test the effectiveness of EmeTerm - neuromodulation technology to manage...
Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology
SUZHOU, China and SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD). Financing was led by Cenova Capital with additional participation from Guangzhou Yuexiu Industrial Investment Fund Management, 3E Bioventures Capital, Oriza Holdings, and Series A investors. Eluminex is a clinical-stage biotechnology...
Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for...
The first case of COVID pregnant mother in Guangzhou was successfully delivered by cesarean section and the newborn was in good condition; doctors treat pregnant COVID-19 patient Under Quarantine...
The First Case of Successful Delivery of Patient with COVID-19 in Guangzhou GUANGZHOU, China, Feb. 27, 2023 /PRNewswire/ -- "Mother and daughter are safe, the child is 2.85 kilograms." In the early morning of November 1st, director of the Department of Obstetrics and Gynecology, Liang Huichao said, and the worried medical staff of the Eighth Affiliated Hospital of Guangzhou...
